Citations

Showing 10 of 108119 citations.

Circulating Tumor DNA Profiling of Advanced Biliary Tract Cancers
Mody, Kabir , Kasi, Pashtoon Murtaza , Yang, Ju-Dong, Surapaneni, Phani Keerthi, Bekaii‐Saab, Tanios , Ahn, Daniel H. , Starr, Jason S. , Roberts, Ali, Nagy, Rebecca J. , Kasi, Pashtoon M, Yang, Judong, Kasi, Pashtoon Murtaza , Bekaii-Saab, Tanios S , Mahipal, Amit , Sonbol, Mohamad Bassam , Lanman, Richard B. , Borad, Mitesh J.

Mayo Clinic

JCO Precision Oncology | March 18, 2019 | Volume: No volume available | Issue: 3 | Pages: 1-9

10.1200/po.18.00324 | PMID 35100741 Get It

PURPOSE Recent advances in molecular diagnostic technologies have allowed for the evaluation of solid tumor malignancies via noninvasive blood sampling, including circulating tumor DNA (ctDNA) profiling. We sought to characterize the ctDNA genomic alteration landscape in patients with biliary tract cancers (BTCs). PATIENTS AND METHODS From January 2015 to February 2018, 124 patients with BTC at the Mayo Clinic Comprehensive Cancer Center underwent ctDNA testing using a clinically available assay. The majority of samples (n = 122) were tested using the 73-gene panel that includes somatic genomic targets, including complete or critical exon coverage in 30 and 40 genes, respectively, and in some, amplifications, fusions, and indels. RESULTS A total of 138 samples were included, with approximately 70% of patients having intrahepatic BTC. All patients had locally advanced or metastatic BTC. Samples with one or more alterations, when variants of unknown significance were excluded, numbered 105 (76%). Each sample contained, on average, three alterations with a median allelic fraction of 0.52%. The overall landscape of alterations is summarized in Figures 1 and 2. After excluding variants of unknown significance, therapeutically relevant alterations were observed in 76 patients (55%), including BRAF mutations, ERBB2 amplifications, FGFR2 fusions, FGFR2 mutations, and IDH1 mutations seen in 21% of patients. A different spectrum of alterations was observed in patients with early-onset BTC (younger than age 50 years) compared with older patients (older than age 50 years). CONCLUSION Data on ctDNA in BTC is currently limited. Our study, the largest cohort reported to date to our knowledge, demonstrates the feasibility of ctDNA testing in this disease. We provide a foundation upon which the field can continue to grow.
Approach to the Examination and Classification of Nystagmus
Eggers, Scott D.Z.

Mayo Clinic

Journal of Neurologic Physical Therapy | March 18, 2019 | Volume: 43 | Issue: No issue available | Pages: S20-S26

10.1097/npt.0000000000000270 | PMID 30883489 Get It

Background and Purpose: Physical therapists caring for patients with neurologic or vestibular disorders must routinely examine and characterize nystagmus and other oscillatory eye movements. Often, the diagnosis hinges on proper interpretation of the nystagmus pattern. This requires understanding the terminology surrounding the numerous attributes and influencing factors of nystagmus, a systematic approach to the examination, and a classification structure that guides practitioners to the specific nystagmus type and subsequent evaluation and management. Summary of Key Points: Nystagmus is an involuntary, rapid, rhythmic, oscillatory eye movement with at least 1 slow phase. Jerk nystagmus has a slow phase and a fast phase. Pendular nystagmus has only slow phases. Nystagmus is distinguished from other types of oscillatory eye movements, such as saccadic intrusions or oscillations. Characterizing nystagmus requires clearly describing its trajectory. This includes choosing a reference frame to describe the axes or planes and direction of eye movements. Several attributes are used to describe nystagmus: binocularity, conjugacy, velocity, waveform, frequency, amplitude, intensity, temporal profile, and age at first appearance. Several factors may influence nystagmus, including gaze position, visual fixation, vergence, and a variety of provocative maneuvers. Classification of nystagmus may be organized by physiologic or pathologic nystagmus versus other nystagmus-like movements. Pathologic nystagmus may be spontaneous, gaze-evoked, or triggered by provocative maneuvers. The combination of attributes allows differentiation between the many peripheral and central forms. Recommendations for Clinical Practice: Therapists should carefully examine and characterize the trajectory and other attributes and influencing factors of nystagmus to accurately classify it and arrive at the correct diagnosis.
Mental Health Disorders are More Common in Colorectal Cancer Survivors and Associated With Decreased Overall Survival
Baraghoshi, David , Garrido‐Laguna, Ignacio , Gilcrease, Glynn Weldon, Whisenant, Jonathan, Weis, John R., Scaife, Courtney L. , Pickron, T. Bartley, Huang, Lyen C. , Monroe, Marcus M. , Abdelaziz, Sarah, Fraser, Alison , Deshmukh, Vikrant , Rowe, Kerry , Snyder, John , Samadder, N. Jewel , Hashibe, Mia, Samadder, Niloy J, Lloyd, Shane , Tao, Randa , Smith, Ken R. , Newman, Michael , Snyder, John

Mayo Clinic

American Journal of Clinical Oncology | March 18, 2019 | Volume: 42 | Issue: 4 | Pages: 355-362

10.1097/coc.0000000000000529 | PMID 30844850 Get It

Objectives: To determine the risk and risk factors for mental illness among colorectal cancer (CRC) survivors across short-term and long-term follow-up periods. Methods: We used the Utah Cancer Registry to identify CRC survivors diagnosed between 1997 and 2013. Mental health diagnoses were available in electronic medical records and statewide facilities data that were linked by the Utah Population Database. CRC survivors were matched to individuals from a general population cohort. The risk of developing a mental illness was compared between cohorts. The association between mental illness and mortality was also analyzed. Results: In total, 8961 CRC survivors and 35,897 individuals in a general population cohort were identified. CRC survivors were at increased risk for any mental health diagnosis at 0 to 2 years (hazard ratio [HR], 3.70; 95% confidence interval [CI], 3.47-3.95), >2 to 5 years (HR, 1.23; 95% CI, 1.09-1.38), and >5 years (HR, 1.20; 95% CI, 1.07-1.36) after cancer diagnosis. CRC survivors were also at increased risk of depressive disorders specifically during the same time periods. At >5 years, CRC survivors still had an increased risk of developing many mental health diagnoses. Factors associated with increased risk of any mental health disorder among CRC survivors included colostomy and Charlson Comorbidity Index of 1+. There was an increased risk of death for CRC survivors diagnosed with any mental health disorder (HR, 2.18; 95% CI, 2.02-2.35) and depression (HR, 2.10; 95% CI, 1.92-2.28). Conclusions: CRC survivors are at increased risk for mental health disorders in the short-term and long-term. Survivors who develop mental health disorders also experience decreased survival.
Incidence and Impact of Acute Kidney Injury after Liver Transplantation: A Meta-Analysis
Kaewput, Wisit , Thamcharoen, Natanong , Cheungpasitporn, Wisit , Watthanasuntorn, Kanramon , Lertjitbanjong, Ploypin , Sharma, Konika , Salim, Sohail Abdul , Ungprasert, Patompong , Kröner, Paul T. , Aeddula, Narothama Reddy , Mao, Michael A. , Kaewput, Wisit , Kröner, Paul T , Aeddula, Narothama Reddy , Mao, Michael A , Cheungpasitporn, Wisit , Thongprayoon, Charat , Wijarnpreecha, Karn

Mayo Clinic

Journal of Clinical Medicine | March 18, 2019 | Volume: 8 | Issue: 3 | Pages: 372

10.3390/jcm8030372 | PMID 30884912 Get It

Background: The study’s aim was to summarize the incidence and impacts of post-liver transplant (LTx) acute kidney injury (AKI) on outcomes after LTx. Methods: A literature search was performed using the MEDLINE, EMBASE and Cochrane Databases from inception until December 2018 to identify studies assessing the incidence of AKI (using a standard AKI definition) in adult patients undergoing LTx. Effect estimates from the individual studies were derived and consolidated utilizing random-effect, the generic inverse variance approach of DerSimonian and Laird. The protocol for this systematic review is registered with PROSPERO (no. CRD42018100664). Results: Thirty-eight cohort studies, with a total of 13,422 LTx patients, were enrolled. Overall, the pooled estimated incidence rates of post-LTx AKI and severe AKI requiring renal replacement therapy (RRT) were 40.7% (95% CI: 35.4%–46.2%) and 7.7% (95% CI: 5.1%–11.4%), respectively. Meta-regression showed that the year of study did not significantly affect the incidence of post-LTx AKI (p = 0.81). The pooled estimated in-hospital or 30-day mortality, and 1-year mortality rates of patients with post-LTx AKI were 16.5% (95% CI: 10.8%–24.3%) and 31.1% (95% CI: 22.4%–41.5%), respectively. Post-LTx AKI and severe AKI requiring RRT were associated with significantly higher mortality with pooled ORs of 2.96 (95% CI: 2.32–3.77) and 8.15 (95%CI: 4.52–14.69), respectively. Compared to those without post-LTx AKI, recipients with post-LTx AKI had significantly increased risk of liver graft failure and chronic kidney disease with pooled ORs of 3.76 (95% CI: 1.56–9.03) and 2.35 (95% CI: 1.53–3.61), respectively. Conclusion: The overall estimated incidence rates of post-LTx AKI and severe AKI requiring RRT are 40.8% and 7.0%, respectively. There are significant associations of post-LTx AKI with increased mortality and graft failure after transplantation. Furthermore, the incidence of post-LTx AKI has remained stable over the ten years of the study.
Association of Atrial Fibrillation With White Matter Disease
Shao, Iris Yuefan , Jack, Clifford R. , Gottesman, Rebecca F. , Chen, Lin Y. , Norby, Faye L. , Soliman, Elsayed Z. , Jack, Clifford R , Gottesman, Rebecca F , Chen, Lin Y , Power, Melinda C. , Mosley, Thomas H. , Alonso, Álvaro

Mayo Clinic

Stroke | March 18, 2019 | Volume: 50 | Issue: 4 | Pages: 989-991

10.1161/strokeaha.118.023386 | PMID 30879437 Get It

Background and Purpose— Evidence suggests that atrial fibrillation (AF) is associated with increased risk of cognitive decline and dementia, even in the absence of stroke. White matter disease (WMD) is a potential mechanism linking AF to cognitive impairment. In this study, we explored the association between prevalent AF and WMD. Methods— We performed a cross-sectional analysis of participants attending the ARIC-NCS (Atherosclerosis Risk in Communities–Neurocognitive Study) in 2011 to 2013 who underwent brain magnetic resonance imaging. AF was ascertained from study visit electrocardiograms or prior hospitalization codes. Extent of WMD was defined by measures of white matter (WM) microstructural integrity and WM hyperintensity volume. Multivariable linear regression models were used to assess the association between AF and WMD. Results— Among 1899 participants (mean age, 76 years; 28% black; 60% women), 133 (7%) had prevalent AF. After multivariable adjustment, differences between participants with and without AF were −0.001 (95% CI, −0.006 to 0.004) for global WM fractional anisotropy, 0.031×10 −4 mm 2 /s (95% CI, −0.075 to 0.137) for global WM mean diffusivity, and 0.08 mm 3 (95% CI, −0.14 to 0.30) for WM hyperintensity volume. Conclusions— The results suggest that there is no association between prevalent AF and WMD.
Statement on imaging and pulmonary hypertension from the Pulmonary Vascular Research Institute (PVRI)
Kiely, David G. , Levin, David L. , Ivy, D. Dunbar , Bwika, Jumaa, Lordan, Jim , Mazurek, Jeremy A. , Moledina, Shahin , Olschewski, Horst , Peacock, Andrew J. , Puri, G. D., Rahaghi, Farbod N. , Schäfer, Michal , Screaton, Nicholas, Noordegraaf, Anton Vonk , Vandepool, Rebecca, Wort, Stephen J. , Zhao, Lan , Wild, Jim M. , Vogel‐Claussen, Jens , Swift, Andrew J. , Vanderpool, Rebecca , Levin, David, Olschewski, Horst , Vonk Noordegraaf, Anton , Vanderpool, Rebecca R , Wild, Jim M , Hassoun, Paul M. , Jone, Pei-Ni , Kawut, Steven M. , Lungu, Angela , Schiebler, Mark , Tawhai, Merryn Howatson , Beek, Edwin J.R. van , Kiely, David , Vogel-Claussen, Jens

Mayo Clinic

Pulmonary Circulation | March 18, 2019 | Volume: 9 | Issue: 3 | Pages: 1-32

10.1177/2045894019841990 | PMID 30880632 Get It

Pulmonary hypertension (PH) is highly heterogeneous and despite treatment advances it remains a life‐shortening condition. There have been significant advances in imaging technologies, but despite evidence of their potential clinical utility, practice remains variable, dependent in part on imaging availability and expertise. This statement summarizes current and emerging imaging modalities and their potential role in the diagnosis and assessment of suspected PH. It also includes a review of commonly encountered clinical and radiological scenarios, and imaging and modeling‐based biomarkers. An expert panel was formed including clinicians, radiologists, imaging scientists, and computational modelers. Section editors generated a series of summary statements based on a review of the literature and professional experience and, following consensus review, a diagnostic algorithm and 55 statements were agreed. The diagnostic algorithm and summary statements emphasize the key role and added value of imaging in the diagnosis and assessment of PH and highlight areas requiring further research.
Determination of fasiglifam-induced liver toxicity: Insights from the data monitoring committee of the fasiglifam clinical trials program
Shavadia, Jay , Sharma, Abhinav , Gu, Xiangqiong, Neaton, James D. , DeLeve, Laurie D. , Holmes, David , Home, Phillip D., Eckel, Robert H. , Watkins, Paul B. , Granger, Christopher B. , Granger, Christopher B

Mayo Clinic

Clinical Trials | March 18, 2019 | Volume: 16 | Issue: 3 | Pages: 253-262

10.1177/1740774519836766 | PMID 30880443 Get It

Background Different approaches to safety event collection influence the determination of liver toxicity within drug development programs. Herein, a description of how fasiglifam-induced liver injury was detected is provided. Methods This eight-trial drug development program was intended to evaluate fasiglifam (25 mg, 50 mg) against placebo or active comparators (glimepiride, sitagliptin) in approximately 11,000 suboptimally controlled patients with type 2 diabetes (terminated Dec 2013 due to liver toxicity). Liver safety had been pre-identified as a concern, and within the phase 3 trials, was measured through (1) adverse event reporting, (2) central predefined liver monitoring schedule with various thresholds for potential drug-induced liver injury, and (3) blinded adjudication of serious liver toxicity by a panel of experts in drug-induced liver injury. A single data monitoring committee provided safety oversight across all trials within the program. Findings Prior to program termination, 7595 of 7602 (99.9%) randomized participants across the eight trials received at least one dose of the study drug (fasiglifam, placebo, or active control). No concerning trends were noted in adverse or serious adverse event frequency, suspected unexpected serious adverse reaction, alanine or aspartate transaminase elevations, or hepatobiliary or gastrointestinal adverse events as reported by local site investigators. However, the predefined central liver safety measurements revealed a greater frequency of possible Hy’s Law cases (5 vs 2) and a 3- to 7-fold greater relative risk in alanine or aspartate transaminase elevation (with respect to upper limit of normal) within fasiglifam recipients compared with placebo/active control: alanine or aspartate transaminase > 3×: relative risk 3.34 (95% confidence interval 2.29–4.90), alanine or aspartate transaminase > 5×: relative risk 6.60 (95% confidence interval 3.03–14.38), alanine or aspartate transaminase > 8×: relative risk 6.14 (95% confidence interval 2.18–17.27), and alanine or aspartate transaminase > 10×: relative risk 6.74 (95% confidence interval 2.05, 22.14). All elevations resolved on study drug discontinuation. Drug-induced liver injury was adjudicated as highly likely or probably related in 0.64% of fasiglifam-treated versus 0.06% placebo or active control-treated patients. Conclusion In spite of clear liver toxicity detected with a systematic surveillance program, liver safety signals were not identified from investigator adverse event reporting alone. By integrating key safety monitoring processes within the randomized design of adequately sized clinical trials, the rare but serious liver toxicity signal became clear, leading to timely program termination.
Independent Effects of Hypertension and Obesity on Left Ventricular Mass and Geometry: Evidence from the Cardiovision 2030 Study
Maugeri, Andrea , Hrusková, J , Jakubík, Juraj , Barchitta, Martina , Re, Oriana Lo , Medina‐Inojosa, José R. , Agodi, Antonella , Sciacca, Sergio, Vinciguerra, Manlio , Medina-Inojosa, Jose R., Vinciguerra, Manlio , Medina-Inojosa, José R , Kunzová, Šárka , Sciacca, Sergio

Mayo Clinic

Journal of Clinical Medicine | March 18, 2019 | Volume: 8 | Issue: 3 | Pages: 370

10.3390/jcm8030370 | PMID 30884768 Get It

Obesity and hypertension independently promote pathological left ventricular remodelling (LVR) and left ventricular hypertrophy (LVH), but to what extent they do so when they do not coexist is unclear. We used data from the Cardiovision Brno 2030 study to assess—for the first time in a region where no investigations have been previously carried out—the independent association of obesity and hypertension with LV geometry, and to evaluate the effects of hypertension in normal weight patients and the effects of obesity in normotensive patients. Overall, 433 individuals, aged 25–65 years, with no history of cardiovascular disease and/or antihypertensive treatment, were stratified into four groups according to BMI and hypertension: normal weight non-hypertensive (NWNH), normal weight hypertensive (NWH), overweight/obese non-hypertensive (ONH) and overweight/obese hypertensive (OH). LVR was classified as normal, concentric LVR (cLVR), concentric LVH (cLVH) or eccentric LVH (eLVH). Linear regression analysis demonstrated that body mass index (BMI) and systolic blood pressure (SBP) are the main predictors of LV mass and that they interact: SBP had a stronger effect in overweight/obese (β = 0.195; p = 0.033) compared to normal weight patients (β = 0.134; p = 0.048). Hypertension increased the odds of cLVR (OR = 1.78; 95%CI = 1.04–3.06; p = 0.037) and cLVH (OR = 8.20; 95% CI = 2.35–28.66; p = 0.001), independent of age, sex and BMI. Stratified analyses showed that NWH had a greater odd of cLVH (OR = 7.96; 95%CI = 1.70–37.08; p = 0.008) and cLVR (OR = 1.62; 95%CI = 1.02–3.34; p = 0.047) than NWNH. In the absence of hypertension, obesity was not associated with LVM and abnormal LV geometry, suggesting that it is not per se a determinant of LVR. Thus, antihypertensive therapy still remains the first-line approach against LVH in hypertensive patients, though weight loss interventions might be helpful in those who are obese.
The Relationship Between Frailty and Decreased Physical Performance With Death on the Kidney Transplant Waiting List
Lorenz, Elizabeth C. , Cosio, Fernando G., Bernard, Shari, Bogard, Steven D., Bjerke, Brian R., Geissler, Elizabeth N., Hanna, Steven W., Kremers, Walter K. , Cheng, Yijing, Stegall, Mark D. , Bernard, Shari L, Stegall, Mark D , Kremers, Walter K , Cheville, Andrea , LeBrasseur, Nathan K.

Mayo Clinic

Progress in Transplantation | March 18, 2019 | Volume: 29 | Issue: 2 | Pages: 108-114

10.1177/1526924819835803 | PMID 30879429 Get It

Introduction: Frailty and decreased physical performance are associated with poor outcomes after kidney transplant. Less is known about their relationship with pretransplant outcomes. The aim of this study was to characterize associations between frailty and physical performance with death on the kidney transplant waiting list. Design: Since December 2014, high-risk kidney transplant candidates at our center (age > 59, diabetic and/or history of >3 years dialysis) have undergone frailty and physical performance testing using Fried Criteria and the Short Physical Performance Battery. Results: Between December 2014 and November 2016, 272 high-risk candidates underwent testing and were approved for transplant. Both frailty and physical performance score were significantly associated with death on the waiting list (hazard ratio [HR]: 6.7, confidence interval [CI]: 1.5-30.1; P = .01; HR: 0.8 per 1-point increase, CI: 0.7-1.0; P = .02, respectively). The relationship between frailty, physical performance score, and death on the waiting list appeared to be independent of age, diabetes, or duration of dialysis. Discussion: Frailty and decreased physical performance appear to be independently associated with increased mortality on the kidney transplant waiting list. Further studies are needed to determine whether improving frailty and physical performance prior to transplant can decrease waiting list mortality.